[Colorectal cancer: irinotecan in combination with newer drugs].
Falcone
A
A
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D000069287:Capecitabine; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D000077146:Irinotecan; D011355:Prodrugs / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D013876:Thiophenes / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D011355:Prodrugs; D011799:Quinazolines; D013876:Thiophenes; D003841:Deoxycytidine; D005641:Tegafur; D014498:Uracil; D000069287:Capecitabine; D000077146:Irinotecan; C068874:raltitrexed; D000068818:Cetuximab; D005472:Fluorouracil; D002166:Camptothecin